<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunologic recovery was studied in ten patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and 23 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e> who received HLA-identical marrow grafts and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> postgrafting as prophylaxis against <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> , 12.5 mg/kg/day, was administered beginning on the day before marrow infusion and continued for 50 days, when it was tapered and discontinued by 6 months postgrafting  </plain></SENT>
<SENT sid="2" pm="."><plain>Results were compared with data from concurrent and previously described patients receiving <z:chebi fb="0" ids="44185">methotrexate</z:chebi> as prophylaxis for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients treated with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> or <z:chebi fb="0" ids="44185">methotrexate</z:chebi> had lower-than-<z:mpath ids='MPATH_458'>normal</z:mpath> immunologic parameters and were not different from one another 3-5 months postgrafting  </plain></SENT>
<SENT sid="4" pm="."><plain>By 11 to 18 months after grafting lymphocyte counts had normalized in both groups </plain></SENT>
<SENT sid="5" pm="."><plain>Serum IgA levels were low and IgG levels had normalized in <z:chebi fb="0" ids="44185">methotrexate</z:chebi>-treated patients, and IgM was <z:mpath ids='MPATH_458'>normal</z:mpath> in <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> -treated patients </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo antibody production to T-dependent antigens and skin test responses to recall antigens continued to be impaired </plain></SENT>
<SENT sid="7" pm="."><plain>The response to the neoantigen <z:chebi fb="0" ids="34718">dinitrochlorobenzene</z:chebi> was still impaired in patients treated with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and <z:mpath ids='MPATH_458'>normal</z:mpath> in patients given <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>These data suggest that immunologic recovery after marrow transplantation is similar in <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> -treated and <z:chebi fb="0" ids="44185">methotrexate</z:chebi>-treated patients </plain></SENT>
</text></document>